However, the antiproliferative activity of 1 on ERα-positive MCF-7 breast cancer cells was 4-fold higher than for tamoxifen (EC50 ≈ 16 μM) and comparable to that of vorinostat (EC50 ≈ 4 μM for both compounds). The gene discussed is ESR1; the disease is breast cancer.